Omni Ax's (532340)
Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹3.7 |
| Market Cap | ₹6.37 Cr |
| P/E Ratio | 0 |
| ROCE | -0.61% |
| ROE | 0.24% |
| Dividend Yield | 0% |
| Profit Growth | 0% |
| Debt/Equity | — |
| Sales Growth | -20% |
| 52-Week Range | ₹3.01 — ₹5.59 |
| Sector | IT - Software |
| Book Value | ₹7.27 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
At ₹3.70 with a market cap of just ₹6 crore, this is a microcap stock—so small that size itself is a risk. The price-to-book ratio is 0.51, meaning I am being offered ₹7.27 of book value for only ₹3.70. In a Graham framework, buying a rupee of assets for fifty paise is interesting. But interest must turn to action only if the assets are real and the business can eventually allocate capital productively. Here, the evidence is not encouraging. Latest quarter sales are zero, net profit is zero, and sales are down 20%. ROCE is negative at -0.61%, while ROE is barely 0.24%. A Piotroski score of 2/9 screams financial stress—this is not a high-quality franchise at work. There is no visible moat: zero revenue generation in the latest quarter suggests the software products business is either dormant or between cycles. The P/E is meaningless because earnings are zero. Dividend is zero, so I get no income while waiting. Debt-to-equity is not available, so I cannot confidently assess balance-sheet risk. The positives are limited: the stock trades far below book value, the 52-week range shows ₹2.70 support, and reported profit is not worsening. However, a low price-to-book ratio in an unprofitable microcap can be a value trap. Graham would demand either an earnings recovery or a clear catalyst to unlock asset value. I would not buy based on this data alone; I would wait for quarterly sales to return and for proof that book value is recoverable.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer